Your browser doesn't support javascript.
loading
Alterations in Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA).
Reitsam, Nic G; Märkl, Bruno; Dintner, Sebastian; Sipos, Eva; Grochowski, Przemyslaw; Grosser, Bianca; Sommer, Florian; Eser, Stefan; Nerlinger, Pia; Jordan, Frank; Rank, Andreas; Löhr, Phillip; Waidhauser, Johanna.
Afiliação
  • Reitsam NG; Pathology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • Märkl B; Pathology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • Dintner S; Pathology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • Sipos E; Pathology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • Grochowski P; Pathology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • Grosser B; Pathology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • Sommer F; General and Visceral Surgery, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • Eser S; Gastroenterology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • Nerlinger P; Hematology and Oncology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • Jordan F; Hematology and Oncology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • Rank A; Hematology and Oncology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • Löhr P; Hematology and Oncology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • Waidhauser J; Hematology and Oncology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
Cancers (Basel) ; 15(3)2023 Feb 03.
Article em En | MEDLINE | ID: mdl-36765951
ABSTRACT

BACKGROUND:

Recently, our group introduced Stroma AReactive Invasion Front Areas (SARIFA) as an independent prognostic predictor for a poorer outcome in colon cancer patients, which is probably based on immunologic alterations combined with a direct tumor-adipocyte interaction the two together reflecting a distinct tumor biology. Considering it is already known that peripheral immune cells are altered in colorectal cancer (CRC) patients, this study aims to investigate the changes in lymphocyte subsets in SARIFA-positive cases and correlate these changes with the local immune response.

METHODS:

Flow cytometry was performed to analyze B, T, and natural killer (NK) cells in the peripheral blood (PB) of 45 CRC patients. Consecutively, lymphocytes in PB, tumor-infiltrating lymphocytes (TILs), and CD56+ and CD57+ lymphocytes at the invasion front and the tumor center were compared between patients with SARIFA-positive and SARIFA-negative CRCs.

RESULTS:

Whereas no differences could be observed regarding most PB lymphocyte populations as well as TILs, NK cells were dramatically reduced in the PB of SARIFA-positive cases. Moreover, CD56 and CD57 immunohistochemistry suggested SARIFA-status-dependent changes regarding NK cells and NK-like lymphocytes in the tumor microenvironment.

CONCLUSION:

This study proves that our newly introduced biomarker, SARIFA, comes along with distinct immunologic alterations, especially regarding NK cells.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha